Anti-HER2 CAR T-cells are an attractive alternative for HER2-low breast cancers, i.e., breast cancers with a HER2 IHC score of 2+ without a positive FISH or a score of 1+. This evidence concerns the gene ERBB2 and breast carcinoma.